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The thyroid hormone receptor (TR)- is a nuclear receptor that mediates both transrepression and
ligand-dependent transactivation. Here we show that TR is posttranslationally modified by acet-
ylation in response to its own ligand (T3).Acetylation increasesbinding toDNA.Usingmutagenesis,
we identified three conserved lysine residues in the carboxi-terminal extension (CTE) of the DNA
bindingdomain that are targets of the cAMP-response element-bindingprotein acetyltransferase.
Substitution of these lysines by arginines in TR decreased ligand binding affinity and precluded
ligand-dependent release of corepressors and recruitment of coactivators. The acetylation TR
mutant lost the ability to transactivate even at high T3 concentrations and acts as a dominant-
negative inhibitor of wild-type TR activity. In addition, whereas native TR interferes with AP-1
function, the mutant is unable to mediate transrepression. Finally, TR suppresses NIH-3T3 fibro-
blast transformation by the Ras oncogene both in a ligand-dependent and -independentmanner,
but the CTE mutant is unable to mediate ligand-dependent repression of transformation. These
results reveal a key role for the CTE region on acetylation, ligand affinity, transactivation, tran-
srepression, and antitransforming properties of TR. (Endocrinology 150: 5143–5152, 2009)
The gene regulatory actions of the thyroid hormone T3are mediated through the binding to nuclear thyroid
receptors, termed thyroid hormone receptor (TR)- and
TR, which are encoded by genes located on human chro-
mosomes 17 and 3, respectively. Transcripts of each of
these genes undergo alternative splicing generating the
TR1 and -2 and TR1 and -2 receptor isoforms (1).
The nuclear receptors have a modular structure with sev-
eral regions (A/B, C, D, and E). The C region contains the
DNA binding domain (DBD), composed of two zinc fin-
gers and a -helical C-terminal extension (CTE) that
makes auxiliary contacts with DNA. Transcriptional reg-
ulation by the receptors is achieved through autonomous
activation functions (AFs): a constitutiveN terminal AF-1
in the A/B region and a ligand-dependent AF-2 located in
the C-terminal E region of the ligand binding domain
(LBD) (1, 2). TRs can regulate gene expression by binding,
preferentially as heterodimers with the retinoid X recep-
tors (RXRs), to specificDNAsequences [thyroid hormone
response elements (TREs)] located in regulatory regions of
target genes (3) and by positive or negative interference
with the activity of other transcription factors such as ac-
tivator protein-1 (AP-1), cAMP response element-binding
protein (CREB) or nuclear factor-B, a mechanism re-
ferred to as transcriptional cross talk (4–10).Whenbound
to TREs the unliganded TR recruits corepressors and re-
ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.
Copyright © 2009 by The Endocrine Society
doi: 10.1210/en.2009-0117 Received January 29, 2009. Accepted August 12, 2009.
First Published Online October 9, 2009
Abbreviations: ACTR, Activator of thyroid and retinoic acid receptor; AF, activation func-
tion; AP-1, activator protein-1; AR, androgen receptor; CAT, chloramphenicol acetyl trans-
ferase; CBP, cAMP-response element-binding protein acetyltransferase; CREB, cAMP re-
sponse element-binding protein; CTE, C-terminal extension; DBD, DNA binding domain;
ER, estrogen receptor; GST, glutathione-S-transferase; HAT, histone acetylase activity;
HDAC, histonedeacetylase; LBD, ligand binding domain; RXR, retinoid X receptor; SAHA,
suberoylanilide hydroxamic acid; SMRT, silencing mediator of retinoid and thyroid recep-
tors; TR, thyroid hormone receptor; TRE, thyroid hormone response element.
T H Y R O I D - T R H - T S H
Endocrinology, November 2009, 150(11):5143–5152 endo.endojournals.org 5143
presses transcription, whereas ligand binding induces a
conformational change in the receptor C-terminal -helix
(helix 12) that leads to the release of corepressors and the
recruitment of coactivators (11, 12). Some nuclear recep-
tor coactivators such as cAMP-response element-binding
protein acetyltransferase (CBP)/p300 and the p160 pro-
teins possess histone acetylase activity (HAT) that cause
chromatindecompaction.CBP/p300proteins acetylatehi-
stones but also p160 coactivators (13) and multiple tran-
scription factors such as p53 (14), cellular transcription
factor involved in adenovirus early region 1A (E1A)
(E2F1; Ref. 15) , p65 nuclear factor-B (NF-B; Ref. 16),
or some nuclear receptors (17–23). Acetylation can regu-
late transcription factor activity by modulating DNA
binding, protein-protein interactions, protein stability or
subnuclear localization (24). The finding that the sirtuins
deacetylase nuclear receptors provides a new level of com-
plexity in the control of nuclear receptor activity (25, 26).
To date, three nuclear receptors have been shown to be
CBP targets: the androgen receptor (AR) (20), the estrogen
receptor (ER)- (22, 23), and TR (27). AR acetylation
occurs in theDBDCTE in aKLKKmotif corresponding to
K630/K632/K633 residues, and mutation on these sites
decreases corepressor binding, augments association with
coactivators, and increases ligand-dependent transactiva-
tion (19). ER acetylation that occurs in K266 and K268
sites corresponding to K632 and K633 in the AR, en-
hances DNA binding activity, and correlates with an in-
crease in transcriptional activity (22). ER contains ad-
ditional sites of acetylation by p300 in K299/ K302/K303
residues, and the mutant K302/K303 shows an increased
estradiol-dependent activation, suggesting a role of ER
acetylation in ligand sensitivity (28).
TRs contain a KRV/LAKRK sequence equivalent to the
KLKK motif in AR corresponding to K184/K188/K190 in
TR and K128/K132/K134 in TR, but in contrast to AR
and ER, little is known about the functional consequences
of TR or TR acetylation. There is one report describing
thyroid hormone-dependent TR acetylation, but residues
responsible for acetylation have not been identified (27).
Hereweshowthat theCTEregionof theTRDBDisalso
a target for acetylation by CBP and that TR acetylation
increasesbindingtoDNA.Amutant intheacetylationregion
shows loss of ligand-dependent transactivation and transre-
pressioncapacityandactsasadominant-negativeonpositive
TREs. In addition, in contrast with the native receptor (29),
the CTE mutant has lost the ability to show increased inhi-
bition of fibroblast transformation by oncogenic Ras in the
presence of hormone.Collectively, our results suggest an im-
portantrole forCTEregionofTR in the transcriptionaland
the antioncogenic actions of this receptor.
Materials and Methods
Plasmids
pSG5-CTE, pSG5K128R, and pSG5K132/134R were gener-
ated from chicken TR by site-directed mutagenesis with the Pfu
Turbo DNA polymerase (Stratagene, La Jolla, CA) by using the
double stranded oligonucleotides: 5-GACGACTCGAGGCGC-
GTAGCCAGGCGGAGGCTGATCGAG-3, 5-GACGACTC-
GAGGCG CGTAGCCAAGCGGAAGCTGATCGAG-3, and
5-GACGACTCGAAGCGCGTAGCCAGG CGGAGGCTGAT-
CGAG-3, respectively. PCR products were digested with DpnI.
The mutations were confirmed by sequencing. pSG5-K232I was
previously described in (29).
Transient transfection assays
HeLa or HEK 293T cells were grown in DMEM containing
10% fetal bovine serum. Cells were transfected with calcium
phosphate. Onemicrogram of the mouse mammary tumor virus
luciferase reporter plasmid containing a thyroid-responsive ele-
ment (MMTV-TREpal-LUC), DR4-tk-LUC (30), 39/12
GH-CATthat contains a fragmentof the ratGHgene (39/12)
fused to chloramphenicol acetyl transferase (CAT) (31), or
73col-luc together with 0.6 g pRL-TK (renilla) were trans-
fected with 0.5 g of expression vectors (pSG5-0, pSG5-TR,
pSG5-CTE, pSG5-K128R, or pSG5-K132/134R). Twelve hours
after transfection, the cells were preincubated in DMEM sup-
plemented with 10%AG1-X8 resin and charcoal-stripped new-
born calf serumand then treatedwithT3 for 36 h. Luciferase and
renilla activity were assayed with a dual-luciferase assay system
(Promega, Madison, WI). CAT activity was determined as pre-
viously described (31).
Synthesis and purification of recombinant proteins
Glutathione-S-transferase (GST)-fusion proteins were puri-
fied from Escherichia coli on glutathione-Sepharose and ana-
lyzed by SDS-PAGE. Alternatively, 35S-labeled proteins were in
vitro generated with the TNT-T7 Quick kit (Promega).
In vitro acetylation assays
GST-fusion proteins or in vitro-translated proteins were in-
cubated with the HAT domain of CBP (1098-1877 fragment)
fused to GST in the presence of [3H]acetyl-CoA in HAT buffer
(15). The reactions were incubated at 30 C for 60 min and were
analyzed in 10%SDS-PAGE. Gels were exposedwith X-OMAT
films (Kodak,Rochester,NY) for 2 d.Acetylation reactionswith
unlabeled acetyl-CoA were carried out under similar reaction
conditions.
In vivo acetylation assays
GH4C1 cells that express endogenous TR and TR were
grown in DMEM supplemented with 10% fetal serum. Twelve
hours prior to T3 and suberoylanilide hydroxamic acid (SAHA)
treatment, cells were incubated with DMEM containing 10%
AG1-X8 resin and charcoal-stripped newborn calf serum. Cells
were treated for24hwith5nMT3and2MSAHAand then lysed
in lysis buffer [50 mMHEPES (pH 8), 600 mMKCL, 0.5%Non-
idet P-40, 1 mM Na3VO4, 1 mM dithiothreitol, protease inhibi-
tors]. Two milligrams of whole-cell lysates were precleared and
incubated overnight with 2g of rabbit IgG or antiacetyl lysine-
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specific antibody. The immunoprecipitated proteins were de-
tected by Western blotting.
Western blot assays
For Western blot assays, cell extracts were prepared in lysis
buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 0.5% sodium do-
decyl sulfate, 30 mM sodium pyrophosphate (PPi), 0.5M NaF,
protease inhibitors], and 5–10gwere loaded into 12% sodium
dodecyl sulfate gels.Membraneswere probedwith the following
antibodies: anti-TR (Santa Cruz Biotechnology, Santa Cruz,
CA), anti-H3 (Millipore, Tennecula, CA), and antiacetylated ly-
sine (-LysAc; Cell Signaling, Beverly, MA).
In vitro pull-down assays
35S-labeled proteins were used in pull-down assays with 1g
of GST or GST-fused proteins as described previously (9).
Band-shift assays
In vitro-translated TR was either unmodified or acetylated
with CBP. One microliter of in vitro-translated RXR together
with 1 g of GST-silencing mediator of retinoid and thyroid
receptors (SMRT) or GST-activator of thyroid and retinoic acid
receptor (ACTR) was added to TR on ice for 15 min before
incubation with a [32P]-end-labeled double-stranded oligonu-
cleotide (5-AGCTCAGGTCACAGGAGGTCAG-3) contain-
ing a consensus TRE sequence for 30 min at room temperature
in the presence or absence of 1 M T3. Similar assays were per-
formed in the absence of RXR. The samples were analyzed on
nondenaturing 5%polyacrylamide gels run in 0.5Tris-borate
EDTA. Alternatively, 0.5 g GST-TR or GST-CTE with GST-
RXR were used.
Protease resistance assay
In vitro-translated TR or CTE mutant were incubated in
absence or presence of 5 nM of T3 with 0.02, 0.01, and 0.5 U
trypsin (Sigma, St. Louis, MO).
Foci formation assays
NIH-3T3 fibroblasts were transfected with calcium phos-
phate and 500 ng of pCEFL-Ha-Rasval12 and 4 g of expression
vectors for TR or with the same amount of empty vector (32).
Cultures were fed with fresh medium containing 10% T3-
stripped donor calf serum every 2 d in the presence or absence of
5 nM T3. At 14 d after transfection, the foci were stained with
Giemsa and scored visually.
125I-T3 binding assays
Binding assayswere essentially performed as described (33, 34).
Statistical analysis
All data are expressed as means  SD. Student’s t test was
performed using the SSC-Stat software (version 2.18; University
of Reading, Reading, UK).
Results
TR is acetylated by CBP in the CTE region
A previous report has shown that TR can be acety-
lated (27). To examine whether TR is also a target for
acetylation, GH4C1 cells were treated for 24 h with 5 nM
T3 alone or in combination with the histone deacetylase
(HDAC) inhibitor SAHA(2M).Acetylatedproteinswere
immunoprecipitated from nuclear extracts with an anti-
body for acetylated lysines, and the acetylated receptor
was detected with a TR-specific antibody. Figure 1A
shows that T3, and to a lesser extent SAHA, increased
acetylated TR (lanes 6–7), whereas acetylated histone
H3 was increased only in the presence of SAHA or SAHA
plus T3 (lanes 7–8). To examine the acetylation sites of
TR, we generated three lysine mutants, one in the DBD
FIG. 1. TR is acetylated in vivo and in vitro. A, Acetylated proteins
were immunoprecipitates (IP) from GH4C1 cells previously treated in
the presence or absence (C) of 5 nM T3, 1 M SAHA (s), and SAHA plus
T3 for 24 h. Western blot (WB) assays were developed with TR and
acetylated H3 antibodies. The input amount is the 10% of the total
extract protein. Quantifications of acetylated TR and H3 (H3Ac) levels
are represented on the graphic. B, Schematic representation of the
location of TR mutations (indicated by asterisks) used in this study.
The DBD and LBD are indicated. C, Quantifications of acetylation
assays with the point and deletion mutants shown in B. GST-TRwt and
mutants were incubated with GST-CBP in the presence of [3H]acetyl-
CoA and CBP. The reactions were analyzed by SDS-PAGE with
subsequent fluorography. wt, Wild type.
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(K105A mutant) equivalent to K128A mutant that is
acetylated in TR, other in the consensus motif KLKK
described for AR and ER in the C-terminal extension of
the receptor DBD (K128/132/134R or CTE mutant), and
other in the conserved K232 residue (K232I) in the LBD
(Fig. 1B). We examined by in vitro acetylation assays the
acetylation of TRwt, these mutants, and one additional
TR mutant corresponding to a deletion of the AF-1 do-
main and the DBD (120-408TR). Quantification of the
results (Fig. 1C) shows that TRwt was acetylated in vitro
by CBP and that the deletion of the N-terminal domain
that contains the AF-1 domain; the mutation K232I in
helix 3or themutationof theK105 residuedidnot prevent
TR acetylation by CBP. However, triple substitution of
lysines 128, 132, and 134 by arginines abolished TR
acetylation. To determine whether one or two residues in
the CTE were essential for acetylation, we generated two
additional mutants, TRK128R and TRK132/134R.
Both mutants show a decrease in acetylation with re-
spect to TRwt, although this decrease was only signif-
icant for the TRK132/134R mutant. However, total
abrogation of TR acetylation was achieved only with
theCTEmutant. These data demonstrate that TR acet-
ylation by CBP occurs in the CTE, in accordance with
previous reports for ER and AR (20, 28).
Acetylation of TR increases DNA binding
Given that the acetylated residues are adjacent to the
DBD, we next tested by band-shift assays whether acety-
lation affected the ability of TR to bind DNA. In these
experiments, in vitro-translatedTRwas acetylated in the
presence of CBP and nonradiactive acetyl-CoA in the ab-
sence or presence of T3. Each reaction was used in band-
shif assays with a 32P-labeled double-stranded oligonu-
cleotide containing a consensus TRE sequence (DR4). In
the absence of hormone, TR binds to the DR4 as a het-
erodimer with RXR with the same affinity independently
of its acetylation state (Fig. 2A, lanes 1 and 4). However,
in the presence of T3 (1 M) and at low receptor concen-
trations, the acetylated receptor binds to the TRE with a
higher affinity than the nonacetylated TR (lanes 2 vs. 5).
Also GST-TR, in the presence of T3, bounds to the DNA
with higher affinity after incubation with acetyl-CoA, but
with T3 and without acetyl-CoA, the binding of TR to
DNA was not increased (Fig. 2B). Next, we performed
band-shift assayswith thewild-type receptor and the acet-
ylationmutant. Again, acetylation increased DNA bind-
ing of the TRwt in a T3-dependent manner, whereas
the hormone did not increase binding affinity of the
receptor that contains a triple mutation in the acetyla-
tion region (CTE) (Fig. 2C), confirming that TR acet-
ylation enhances binding of the heterodimer to a con-
sensus TRE. Because TR can also bind as a homodimer
to this element, we performed the assay under similar
conditions but in the absence of RXR. Binding of ho-
modimers to the TRE was not modified after TR acet-
ylation (Fig. 2D).
The CTE of TR is important for the interaction
with coactivators and corepressors
In the absence of ligand, TR is bound to corepressor
proteins [SMRT or nuclear receptor corepressor (NCoR)]
associated with HDACs (35, 36), repressing gene tran-
scription. Receptor occupancy by T3 results in dissocia-
tionof corepressors andderepression, followedby recruit-
ment of coactivators and associated cofactors, some of
which exhibit HAT activity, leading to transcriptional ac-
tivation. We next examined the ability of TR-RXR and
CTE-RXR heterodimers to recruit coactivators when
bound to the consensus direct repeat TRE (Fig. 3A).Wild-
type TR-RXR complexes recruited aGST-fusion protein
containing the receptor-interacting domain of the p160
coactivator ACTR (GST-ACTR, residues 621-821) in a
T3-dependent manner (lane 4). In this assays the amount
of ACTR used was sufficient to observe binding of ACTR
to the wild-type heterodimer, even in the absence of hor-
mone (lane 3). In contrast to TRwt-RXR, recruitment of
GST-ACTR by the CTE-RXR heterodimer was not de-
tected either in the absence or presence of hormone (lanes
9 and 10). These results were also analyzed in pull-down
assays with S35-methionine in vitro-translated receptors
(Fig. 3B). TR bound detectably ACTR in the absence of
hormoneand this interaction increased afterT3 treatment,
FIG. 2. Acetylated TR shows increased DNA binding activity in the
presence of T3. A, One and 2.5 l of TR nonacetylated or acetylated
in vitro with CBP and acetyl-CoA were used in band-shift assays
together with 1 l of in vitro-translated RXR in the absence or
presence of T3. B, TR binding was analyzed after incubation with
CBP, and the presence or absence of acetyl-CoA C, GST-TR, or GST-
CTE was acetylated in vitro and the binding to the TRE as heterodimers
with RXR was analyzed in the absence and the presence of T3. D, TR
(2 l), nonacetylated or acetylated, was incubated with or without T3
in the absence of RXR and used in band-shift assays.
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whereas the CTEmutant showed less interaction with co-
activators than thewild-type receptor, and this interaction
did not increase in the presence of hormone. Pull-down
quantification (Fig. 3C) showedagain the reducedbinding
of coactivators by the unliganded mutant receptor as well
as the lack of response to T3. The low interaction between
the CTE mutant and ACTR was not sufficient for detec-
tion as a supershift in the band shift.
We also compared the binding of wild-type and CTE
mutant receptors to corepressors.We observed that in the
absence of T3, the CTEmutant and the wild-type receptor
bound the corepressor SMRT with similar affinity (Fig.
3A, lanes 5 and 11). However, whereas TRwt was able
to release SMRT very efficiently after T3 incubation, the
CTE mutant remained bound to SMRT, even in the pres-
ence of 1 M T3 (lanes 6 and 12). In pull-down assays, the
CTE mutant bound the corepressor with even higher af-
finity than the native TR but in coincidence with the
results obtained in band-shift assays was not able to re-
lease SMRT in the presence of hormone (Fig. 3, B–D).
Protease and binding assays
Although the CTE mutations are outside the LBD, the
fact that in the presence of hormone, the CTE mutant did
not show increased coactivator recruitment and was not
able to release corepressors suggested that the primary
defect of thismutantmightbe inhormonebindingaffinity.
To check that possibility, we used two experimental ap-
proaches, a protease protection assay in which T3 binding
is measured through its ability to generate a protease-re-
sistant conformation in the receptor (Fig. 4, A and B) and
binding assays with I125-T3 to determine receptor affinity
(Fig. 4, C and D). In vitro-translated TRwt or CTE mu-
tantwere digested in thepresenceof increasing amounts of
trypsin. In the absence of T3, both wild-type and mutant
TR were efficiently degraded by protease digestion. In-
cubation of TRwt with T3 resulted in formation of a
protease-resistant polypeptide that progressively disap-
peared in function of increasing amounts of trypsin.How-
ever, the CTE mutant in the presence of hormone was
totally digested, even at the lowest amount of protease
used. Figure 4B shows the quantification of three exper-
iments. To confirm the results obtained in the protease
assays, the capacities of both receptors to bind thyroid
FIG. 4. The CTE mutant shows reduced T3 binding. A, T3 binding by
wild-type (wt) and CTE mutant receptors was determined using
hormone-mediated protease resistance assays. B, The percentage of
input TR remaining after digestion with increased amounts of trypsin
at 1 M T3 concentration was quantified. The data are the mean values
corresponding to three different experiments. C, Scatchard plot of
[125I]T3 binding to TRwt protein synthesized in vitro. Aliquots of the
lysates were incubated overnight at 4 C with different concentrations
of [125I]T3. Nonspecific binding was measured in the presence of a
500-fold excess of T3. The ratio between the amount of [125-I] T3
bound (B) and free (F) is represented in y-axis (B/F). D, Kinetic curves of
TRwt and CTE mutant.
FIG. 3. Altered coactivator interaction and impaired release of
corepressors by the CTE mutant. A, A labeled oligonucleotide spanning
the DR4 element was incubated with in vitro-translated and acetylated
TRwt/RXR or CTE/RXR heterodimers in the presence of GST-0, GST-
ACTR, or GST-SMRT. When indicated, the binding reactions were
carried out in the presence of 1 M T3. The mobility of TR/RXR, TR/RXR/
ACTR, and TR/RXR/SMRT complexes is indicated. B, GST-0, GST-ACTR,
and GST-SMRT were incubated with S35-labeled TRwt or CTE mutant.
C and D, Pull-down quantification corresponding to the TR/ACTR, TR/
SMRT, CTE/ACTR, and CTE/SMRT complexes in the presence of 1 M
T3. Data were corrected with the corresponding inputs and are
expressed relative to the values obtained with the unliganded wild-
type receptor. Data (means  SD) are the result of three different
experiments.
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hormone were assessed. The same amounts of in vitro-
translated receptors, as determined by Met-S35 incorpo-
ration, were tested for their ability to bind hormone by
incubationwith increasing concentrationsof 125I-T3 in the
presence and absence of a 500-fold molar excess of unla-
beled hormone. To determine accurately the effect of the
mutations on hormone binding, we performed Scatchard
and kinetic analyses (Fig. 4, C and D). The dissociation
constant obtained for TRwas 0.25 nM,whereas the CTE
mutant exhibited no detectable binding activity. These re-
sults indicate that the sameresidues in theCTEofTR that
are the target of acetylation by CBP appear to be also
important for ligand binding.
The TR acetylation sites regulate
TR transactivation and
transrepression
Because the acetylation of TR in-
creases DNA binding activity and the
CTE mutant does not recruit coactiva-
tors in a DNA element, we investigated
the effect of mutation of the acetyla-
tion residues on transactivation. HeLa
cells that do not express endogenous
TRs were transiently transfected with a
luciferase reporter plasmid that contains
a palindromic TRE (MMTV-TREpal-
LUC) together with expression vectors
for TRwt or the CTEmutant (Fig. 5A).
As expected, TR induced reporter ac-
tivity in the presence of T3. Conversely,
the CTEmutant was not able tomediate
T3-dependent transactivation, showing
that K128/132/134 residues play an im-
portant role in regulating the transcrip-
tional activity of TR. Interestingly, the
native and mutant receptors were equally
able torepressbasalreporteractivity inthe
absence of T3, in agreementwith the find-
ing that the CTE mutant binds corepres-
sors constitutively.Western blot analysis
showed that wild-type and mutant TR
were expressed at similar levels after
transfection (Fig. 5B). Collectively our
results demonstrate a good correlation
between the decreased DNA binding
and coactivator recruitment with trans-
activation activities of the CTE mutant
when compared with wild-type TR.
Because promoter-selective effects have
beenobserved for theARacetylation site
mutants (17), HEK293T cells that do
not express endogenous TR were tran-
siently transfected with both receptor
expression plasmids in the presence of a different TR re-
ceptor target, the DR4-tk-LUC construct (Fig. 5C). The
results were similar to those observed in HeLa cells with
theMMTV-TREpal-LUC reporter gene, showing that the
lack ofCTE transactivation activitywas not dependent on
cell or promoter type as has been previously shown forAR
acetylation mutants. Trying to compensate for reduced
binding affinity of the CTE mutant, we treated cells with
a higher amount of T3 (Fig. 5C). Even after incubation
with 100 nM T3, the CTE mutant was unable to mediate
ligand-dependent transactivation. In addition, when co-
transfected with equimolecular amounts of TRwt, the
FIG. 5. TR acetylation mutant exhibits altered transcriptional activation and repression and
acts as a dominant negative. A, An empty pSG5-0 vector, pSG5-expressing wild-type TR, or
pSG5-expressing CTE mutant was transfected in HeLa cells together with a MMTV-TREpal-
LUC construct. After transfection the cells were treated with medium alone or 100 nM T3
(black bars) and after 36 h were harvested for luciferase assay. All experiments were
repeated at least three times in duplicate, and all data are presented as the mean  SD.
B, After transfection, the expression of TR wild-type or CTE mutant levels was analyzed by
Western blot. C, DR4tk-LUC was cotransfected with equal amounts of pSG5-TRwt or pSG5-
CTE mutant in HEK 293T cells. After transfection cells were treated with 10 and 100 nM T3.
Data are represented as fold of induction with respect to basal levels in untreated cells.
D, HEK293T cells were cotransfected with the reporter construct and expression vectors for
TRwt or the CTE mutant, and luciferase activity was determined in cells incubated with 10 nM T3
and/or 1 M SAHA, as indicated. E, HEK293T cells were transfected with DR4tk-LUC and
expression vectors for TRwt or the CTE, K128R, and K132,134R mutants. F, HeLa cells were
transfected with the reporter plasmid containing 39 bp 5 from the start of transcription of the
GH promoter (39GH-CAT). The plasmid was cotransfected with an expression vector for TR or
for the CTE mutant and CAT activity determined in control cells and in cells treated with 100 nM
T3. G, Luciferase activity was determined in HeLa cells transiently transfected with a collagenase-
3-LUC reporter together with TRwt or the CTE mutant in absence or presence of 100 nM T3.
Luciferase activity was always corrected by renilla activity.
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acetylation mutant acted as a dominant negative, even at
high hormone concentrations. HEK293T cells were also
treated with 1 M SAHA in the presence or absence of T3
after transient transfection with the DR4-tk-luc construct
(Fig. 5D). SAHA significantly induced transcriptional ac-
tivation of the reporter gene by T3 in cells expressing
TRwt, whereas it had no effect in cells expressing the
CTE mutant. Additionally, we compare transactivation
byTRwt and the threemutant receptors in theCTE region
(Fig. 5E). Whereas activity of the DR4-tk LUC reporter
gene was strongly increased in the presence of hormone
after expression of TRwt or the K128R mutant, the
TRK132/134Rmutant exhibited a significantly decreased
reporter activity in response to T3, and this response was
completely suppressed with the CTE mutant.
TRs can repress transcription through binding to neg-
ative TREs present in the promoter region of T3-regulated
genes, or through transcriptional interference with other
transcription factors such as AP-1. To assess the effect of
the CTE mutant on repression, we used a CAT reporter
construct comprising the 39/12 sequence of the GH
promoter that contains a negative TRE element (31, 37).
A common finding is that on negative TREs the unoccu-
pied receptor increases transcription and the ligand re-
verses this stimulation (38, 39). As shown in Fig. 5F, TR
cotransfection induced basal activity that was reverted by
hormone treatment. In contrast, the CTE mutant did not
induce the basal activity and was unable to respond to T3.
Given the important role of AP-1 complexes in the control
of cell proliferation, we also checked the transrepression
properties of the CTEmutant on activity of the AP-1 con-
taining collagenase promoter (Fig. 5G). TRwt is known
to enhance AP-1 activity in the absence of hormone and
repress in the presence of T3 (7, 40, 41). As expected,
expression of native TR induced basal activity of the
collagenase promoter that was reverted in the presence of
hormone. In contrast, the CTE mutant displayed a very
modest induction of basal transcription and T3 treatment
had not a significant effect. Thus, the CTE mutant is de-
fective both in the ability to enhance AP-1 function in the
absence of hormone and to suppress in the presence of
hormone.
The CTE mutant does not mediate
ligand-dependent inhibition of ras-mediated
fibroblast transformation
We previously described that TRs can inhibit Ras-medi-
ated cellular transformation (32). Therefore, we checked
whether TR acetylation is also important in this process.
For this purpose, we performed foci formation assays with
NIH-3T3 fibroblasts transfected with H-rasval12 alone or
in combination with TR or the CTE mutant (Fig. 6). As
expected, the transforming ability of the ras oncogenewas
greatly reduced in cells coexpressing the native receptor.
TR reduced formation of transformation foci in the ab-
sence of exogenously added T3, and this reduction was
stronger in T3-treated cells. In contrast, although in the
absence of hormone the CTE mutant also caused re-
duction of foci formation, T3 was unable to induce a
further inhibition.
Discussion
Our results show that TR is acetylated in vitro by CBP at
residues Lys128, 132, and 134 (Fig. 1). The acetylation
residues are part of aKRV/LAKRKmotif in theCTEof the
DBD also present in several members of the steroid recep-
tors family. In fact, it is described that both AR and ER
are acetylated in the same region (19, 22). In vivo the
acetylation of the TR receptor is induced by its own li-
gand (T3). It is known that this nuclear receptor recruits
coactivators in a ligand-dependentmanner. Thus, after T3
treatment the recruitment of CBP or other coactivators
with HAT activity could induce TR acetylation. In co-
incidence with TR, the K105A mutant in TR, equiva-
lent to K128A mutant in TR that is acetylated in vivo
(27), was also efficiently acetylated in vitro by CBP. TR
acetylation sites have not beendefined, andwe cannot rule
out thatTR couldbeacetylated indifferent regions ashas
beendemonstrated forER (22,28). In contrast fromTR
FIG. 6. TRwt but not the CTE mutant is able to reduce foci formation
in the presence of T3. A, Foci formation by NIH-3T3 cells transfected
with val12H-ras and pSG5-TR or pSG5-CTE expression vectors. Cells
were treated for 15 d with 5 nM T3. B, Quantitation of foci number.
Rasval12, Valine 12 rat sarcoma. The statistical significance of difference
between untreated cells groups was expressed by #, and that of the
difference between T3-treated cells groups was shown by * (#,*,
0.01 P 0.05; ##,**, 0.001 P 0.01; ###,***, P 0.01).
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that is transiently acetylated in response to thyroid hor-
mones (27), we observed induction of TR acetylation,
even after 36 h incubation with T3. In general, our results
reinforce the idea that specific ligands seem to induce acet-
ylation of their cognate nuclear hormone receptor.
The acetylation of proteins such as cellular transcrip-
tion factor involved in adenovirus early region 1A (E1A)
(E2F1; Ref. 15), MyoD, or ER augments DNA binding
(15, 22, 42), although other proteins such as yin yang
(YY1) and Forkhead box O (FOXO) show a decreased
binding when acetylated by CBP (43, 44). In accordance
with the results described for ER, in the presence of li-
gand, the heterodimeric binding of TR toDNA increases
when the receptor is acetylated (Fig. 2B). Interestingly,
homodimeric binding does not appear to be affected by
acetylation. In some receptors the CTE of the DBD con-
tributes to DNA binding and dimer stabilization (45).
However, in the ternary complex of TR with RXR and
DNA, the CTE region of TR does not participate in the
dimer interface and makes nonspecific contacts with the
DNAbackbone (46). Our results show that in the absence
of hormone, the mutation of the acetylation residues
K128/132/134R in the CTE does not alter affinity of het-
erodimeric binding to a consensus DNA element com-
pared with TRwt. However, binding of the mutant re-
ceptor is not increased by T3 in the presence of CBP and
acetyl-CoA, suggesting again that modification by acety-
lation could enhance TR binding to DNA and transac-
tivation at a target promoter. Alternatively, the CTE mu-
tant could exhibit altered ligand binding properties.
An unexpected finding in this work was that the CTE
mutant, which mimics unacetylated TR, shows a highly
reduced T3 binding affinity and sensitivity. In the case of
ER andAR, themutation at the same acetylation region,
which is outside the LBD, does not appreciably affect li-
gand binding affinity. However, a recent report (47)
shows that deletion of the 629-RKLKKLGN-636 region
in AR, which contains the acetylation residues, enhances
the intramolecular interaction between the amino-termi-
nal domain and the LBD increasing ligand sensitivity of
the mutant with respect to the wild-type receptor. In this
sense, our data show that the CTE domain of the TR
receptor is also crucial for ligand recognition. Addition-
ally, it has been previously shown that residues 120-199 in
TR are required for ligand binding (48) and that the D
domain adjacent to the CTE has an important role in sta-
bilizing the overall structure of the LBD (49). It is then
plausible that an altered receptor conformation that pre-
cludes hormone binding to the LBD could be acquired by
mutation of the CTE acetylation residues. Although crys-
tallographic analysis would be necessary to demonstrate
this hypothesis, the finding that, as observed in Fig. 3B, the
CTE mutant shows a different mobility with respect to
TRwt appears to support this possibility. An important
change in receptor conformation bymutation of the lysine
residues in theCTE is also indicated by the altered binding
of coactivators of the mutant receptor. In in vitro assays,
the acetylationmutant showed a highly reduced affinity
by theACTRcoactivatorwith respect towild-typeTR,
even in the absence of T3, and in a DNA element, the
CTE mutant is completely unable to recruit ACTR.
Probably, as a consequence of the decreased hormone
affinity, the mutant receptor CTE also shows a defect in
corepressor release. TR recruits corepressors in the
absence of hormone, and after ligand binding the core-
pressors are released favoring the coactivator binding.
The TR acetylationmutant shows a constitutive binding
to corepressors, even in thepresenceofhormone.A similar
behavior has been also observed in other receptors such as
AR, in which the acetylation mutant shows enhanced re-
cruitment of nuclear receptor corepressor (NCoR)/phos-
phorylated mothers against decapentaplegic (Smad)/
HDAC-1 complexes and reduced p300 binding compared
with the wild-type AR (19).
The AR acetylation site is required for androgen-me-
diated gene activation (19, 50). The mutant TR in the
CTE lysine residues is also unable to transactivate a TRE-
containing reporter gene in a T3-dependent manner. The
decrease in ligand affinity of the TR acetylation mutant
is coincident with the behavior of some naturally occur-
ringmutants detected in human hepatocellular carcinoma
cells (51). These mutants also show decreased ligand af-
finity and failure to transactivate a TRE-containing target
gene and act as dominant negatives on TR-mediated tran-
scription. Interestingly, the CTE mutant is not able to
transactivate and also acts as a dominant negative of
TRwt mediated transcription. The CTEmutant shows a
strong dominant-negative activity despite the finding that
acetylation increases DNAbinding in vitro. BecauseDNA
binding appears to be required for dominant-negative ac-
tivity, the possibility that TR acetylation does not en-
hanceDNAbinding in the living cell or that little of DNA-
bound TR is acetylated, even in the presence of T3,
cannot be dismissed. On the other hand, due to the in-
ability of the CTEmutant to bind hormone and exchange
corepressors by coactivators is not possible to affirm that,
as in the case of other nuclear receptors, acetylation is
required for ligand-dependent transactivation.
Another interesting property of theCTEmutant is that,
unlike the wild-type receptor, the unliganded acetylation
mutant does not stimulate the core GHpromoter contain-
ing a negative TRE and that it has lost the ability of en-
hancing basal AP-1 activity. The molecular mechanisms
underlying the transcriptional effects of the unliganded
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receptors are not well understood. There is the possibility
that receptor acetylation could be required in vivo for this
ligand-independent effect, but the finding that the acety-
lation residues were also required in vitro to observe in-
teraction with coactivators again suggests that it could be
secondary to the important role of these residues on over-
all receptor structure and stability.
Besides lacking ligand-independent activation on neg-
ative elements or AP-1 motifs, the CTE mutant does not
mediate ligand-dependent transrepression. It is well
known that AP-1 complexes play a central role in the con-
trol of normal cell proliferation, survival, and oncogene-
sis. Wild-type TRs enhance c-Jun/AP-1 activity in the ab-
sence of T3 but inhibit this activity in the presence of T3
(5, 7, 52).We have demonstrated that the acetylationmu-
tant has a strongly reduced ability to stimulate AP-1 ac-
tivity in the absence of hormone and has completely lost
the ability to suppress AP-1 function in the presence of T3.
Therefore, this mutant that acts as a dominant-negative
receptor of the wild-type TR in transactivation could also
interfere with the antiproliferative effects of the liganded
TRsandmayallowgenes involved in cell proliferation and
survival to be expressed under T3 conditions that would
normally be growth suppressive. The CTE mutant not
only does not inhibit AP-1 activity but also is not able to
inhibit fibroblast transformation in the presence of phys-
iological doses of T3, showing that the lysine residues are
also required for ligand-dependent antitransforming ef-
fects of TR, although the mutant receptor maintains the
ability to reduce transformation in the absence of ligand.
In summary, our results show that TR can be acety-
lated in the CTE and that ligand binding stimulates recep-
tor acetylation and increases heterodimeric binding to its
cognate element. Becausemutation of the residues that are
targets for acetylation also alters ligand binding and as-
sociation with coactivators and corepressors, a direct
functional role of acetylation on ligand-dependent tran-
scriptional activation or repression cannot be unambigu-
ously established in the case of this receptor. More signif-
icantly, our results reveal the important and unexpected
role of the CTE region on receptor conformation that af-
fects ligand affinity, transactivation, transrepression, and
antitransforming properties of TR.
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